This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dow Closes at New High as Q2 Earnings Season Heats Up
by Mark Vickery
Earnings season only picks up steam in the weeks to come.
Q2 Earnings Parade Continues
by Zacks Equity Research
Q2 Earnings Parade Continues
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Kinjel Shah
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Pre-Markets Up as 1st Full Week of Q2 Earnings Begins
by Mark Vickery
Goldman Sachs (GS) and BlackRock (BLK) both beat on Q2 earnings this morning, and we're just getting started.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
3 Key Earnings Reports to Watch Next Week
by Derek Lewis
With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $149.43, indicating a +1.62% shift from the previous trading day.
Will Q2 Earnings Power Dow ETFs?
by Sweta Killa
The Dow Jones is underperforming the other large-cap indices, such as the S&P 500 and Nasdaq Composite Index. Can the upcoming Q2 earnings help the index to catch up?
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
by Kinjel Shah
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.
Do Options Traders Know Something About Johnson & Johnson (JNJ) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Johnson & Johnson (JNJ) stock based on the movements in the options market lately.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
by Kinjel Shah
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
by Zacks Equity Research
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
by Zacks Equity Research
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE